Zacks: Brokerages Expect Keryx Biopharmaceuticals (KERX) Will Post Earnings of -$0.13 Per Share

Equities research analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to report ($0.13) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for Keryx Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.15). Keryx Biopharmaceuticals reported earnings per share of ($0.20) during the same quarter last year, which suggests a positive year over year growth rate of 35%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.58). For the next year, analysts expect that the company will post earnings of ($0.01) per share, with EPS estimates ranging from ($0.33) to $0.36. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). The business had revenue of $25.75 million during the quarter.

A number of brokerages have commented on KERX. Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 2nd. BidaskClub raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 11th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Thursday, August 9th. Finally, Citigroup reduced their price objective on Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, August 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $6.25.

A number of institutional investors have recently made changes to their positions in the business. Northern Trust Corp boosted its holdings in shares of Keryx Biopharmaceuticals by 8.8% in the 2nd quarter. Northern Trust Corp now owns 1,190,143 shares of the biopharmaceutical company’s stock worth $4,476,000 after purchasing an additional 96,580 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Keryx Biopharmaceuticals by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,056,811 shares of the biopharmaceutical company’s stock worth $3,974,000 after purchasing an additional 102,014 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Keryx Biopharmaceuticals by 57.6% in the 2nd quarter. Bank of America Corp DE now owns 292,056 shares of the biopharmaceutical company’s stock worth $1,098,000 after purchasing an additional 106,737 shares in the last quarter. Abrams Capital Management L.P. boosted its holdings in shares of Keryx Biopharmaceuticals by 2.4% in the 2nd quarter. Abrams Capital Management L.P. now owns 9,950,055 shares of the biopharmaceutical company’s stock worth $37,412,000 after purchasing an additional 230,879 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 8.8% in the 2nd quarter. BlackRock Inc. now owns 6,613,445 shares of the biopharmaceutical company’s stock worth $24,866,000 after purchasing an additional 534,831 shares in the last quarter. 59.41% of the stock is owned by hedge funds and other institutional investors.

Shares of Keryx Biopharmaceuticals stock opened at $2.90 on Friday. Keryx Biopharmaceuticals has a 52 week low of $2.76 and a 52 week high of $6.60.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Further Reading: Inflation

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply